PFO
GRCL

Pathstone Family Office’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Pathstone Family Office’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$142K Buy
49,158
+23,245
+90% +$85K ﹤0.01% 1558
2023
Q2 		$98.7K Buy
+25,913
New +$72.6K ﹤0.01% 1191

Other funds holding GRCL

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Pathstone Family Office's GRCL Position: Q3 2023 in Review

Pathstone Family Office increased its Gracell Biotechnologies Inc. American Depositary Shares (GRCL) stake by 90% in Q3 2023, buying an estimated $85K and bringing the position to 49,158 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #1558.

Pathstone Family Office first reported a position in GRCL in Q2 2023 and has held it in 2 quarters since. 45 funds tracked by Wall St. Rank hold GRCL as of Q3 2023.

  • Pathstone Family Office held 49,158 shares of Gracell Biotechnologies Inc. American Depositary Shares worth $142K as of Q3 2023.
  • Pathstone Family Office bought 23,245 Gracell Biotechnologies Inc. American Depositary Shares shares in Q3 2023, an estimated $85K.
  • Gracell Biotechnologies Inc. American Depositary Shares made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1558 holding.
  • Pathstone Family Office first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q2 2023 and has held it in 2 quarters since.
  • 45 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.